Collecting and sharing information about harms

British Medical Journal

Volumn 329, Issue 7456, 2004, Pages 6-7

  Pirmohamed, Munir ^a   Darbyshire, Janet ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; DEVELOPING COUNTRY; DRUG INFORMATION; DRUG SURVEILLANCE PROGRAM; EDITORIAL; HARM REDUCTION; HEALTH CARE SYSTEM; HOSPITAL ADMISSION; HUMAN; MEDICAL INFORMATION; MEDICAL PROFESSION; PATIENT MONITORING; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL;

EID: 3042722190     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.329.7456.6     Document Type: Editorial

References (12)

1. Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? J R Coll Phys Lond 1995;29:41-9.
2. Wiffen P, Gill M, Edwards J, Moore A. Adverse drug reactions in hospital patients. A systematic review of the prospective and retrospective studies. Bandolier Extra 2002:1-16.
3. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20.
4. Jefferys DB, Leakey D, Lewis JA, Payne S, Rawlins MD. New active substances authorized in the United Kingdom between 1972 and 1994. Br J Clin Pharmacol 1998;45:151-6.
5. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA 1999;281:1728-34.
6. Report of an independent review of access to the yellow card scheme. London: Stationery Office, 2004.
7. Lee A, Bateman DN, Edwards C, Smith JM, Rawlins MD. Reporting of adverse drug reactions by hospital pharmacists: pilot scheme. BMJ 1997;315:519.
8. Morrison-Griffiths S, Walley TJ, Park BK, Breckenridge AM, Pirmohamed M. Reporting of adverse drug reactions by nurses. Lancet 2003;361:1347-8.
9. Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol 2004;57:127-34.
10. Cuervo LG, Clarke M. Balancing benefits and harms in health care. BMJ 2003;327:65-6.
11. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003;23:686-9.
12. Peto J, Fletcher O, Gilham C. Data protection, informed consent, and research. BMJ 2004;328:1029-30.